Addition of pamidronate to chemotherapy for the treatment of osteosarcoma

✍ Scribed by Paul A. Meyers; John H. Healey; Alexander J. Chou; Leonard H. Wexler; Pamela R. Merola; Carol D. Morris; Michael P. Laquaglia; Michael G. Kellick; Sara J. Abramson; Richard Gorlick

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 183 KB
• Volume: 117
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.25744

✦ Synopsis

Abstract

BACKGROUND:

This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma.

METHODS:

The authors treated 40 patients with osteosarcoma with cisplatin, doxorubicin, and methotrexate with the addition of pamidronate 2 mg/kg/dose (max dose 90 mg) monthly for 12 doses. Survival, event‐free survival (EFS), and durability of orthopedic reconstruction were evaluated.

RESULTS:

For patients with localized disease, event‐free survival (EFS) at 5 years was 72% and overall survival 93%. For patients with metastatic disease, EFS at 5 years was 45% and overall survival 64%. Toxicity was similar to patients treated with chemotherapy alone. Thirteen of 14 uncemented implants demonstrated successful osteointegration. Among allograft reconstructions, there were 2 graft failures, 4 delayed unions, and 6 successful grafts. Overall, 5 of 33 reconstructions failed. There were no stress fractures or growth disturbances.

CONCLUSIONS:

Pamidronate can be safely incorporated with chemotherapy for the treatment of osteosarcoma. It does not impair the efficacy of chemotherapy. Pamidronate may improve the durability of limb reconstruction. Cancer 2011. © 2010 American Cancer Society.